Nanologica was founded in 2004. The company grew out of Dr. Alfonso Garcia-
Bennett’s research, which focused on the synthesis and application of new porous materials and the development of industrially relevant applications.

The starting point for Nanologica’s work is material science, a field in which the
company’s founder has developed and patented completely new materials. The initial research was based at Stockholm University and the Ångström laboratories at
Uppsala University.

In 2011, Nanologica shifted focus from carrying out research on the material to
building a robust commercial operation. A new management team was recruited by 2012, and operations focused on analytical chromatography and drug delivery.


2004 – 2009

Nanologica underwent an orientation phase during which the various possibilities and options were evaluated. Nanologica started to concentrate its efforts on solar cells and drug delivery. Exeger (solar cells) was formed with Nanologica as the major owner.


The first studies in drug delivery, NLAB Silica™, were carried out. The company’s shareholding in Exeger was distributed to Nanologica’s shareholders.


Since 2012, Nanologica has conducted the NLAB Saga™ development project, which aims to develop a silica particle for chromatographic use, specifically for what is known as analytical chromatography.

Together with a research group at Stockholm University led by Professor Tore
Bengtsson, 2012-2014, Nanologica conducted a series of experiments which showed that silica has the potential to treat obesity.

Sigrid Therapeutics, a subsidiary, was founded in 2014 to create a clear and
commercial focus for the success in treating overweight and obese individuals.

At the start of 2015, Nanologica received an important confirmation of NLAB Silica™ technology (drug delivery) when a customers decided to take a test project for a generic drug to the clinical development phase.

The project, NanoALS, was launched in 2015. This project has the potential to develop a treatment which would entail ALS no longer being regarded as a fatal disease but a chronic disease.